Symdeko vs. Orkambi

Symdeko (tezacaftor/ivacaftor tablets and ivacaftor tablets) and Orkambi (lumacaftor/ivacaftor) are combinations of cystic fibrosis transmembrane conductance regulator (CFTR) potentiators indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation.

Symdeko is also used to treat patients with cystic fibrosis who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitrodata and/or clinical evidence.

Side effects of Symdeko and Orkambi that are similar include nausea and stuffy nose.

Side effects of Symdeko that are different from Orkambi include headache and dizziness.

Side effects of Orkambi that are different from Symdeko include shortness of breath, sore throat, diarrhea, upper respiratory tract infection, fatigue, abnormal breathing, increased blood creatine phosphokinase, rash, gas, runny nose, flu symptoms, and increases in blood pressure.

Both Symdeko and Orkambi may interact with antifungals, antibiotics, rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, St. John's wort, and digoxin.

Symdeko may also interact with grapefruit, Seville oranges, cyclosporine, everolimus, sirolimus, and tacrolimus.

Orkambi may also interact with benzodiazepines, immunosuppressants, corticosteroids, ibuprofen, antidepressants, hormonal contraceptives, oral hypoglycemics, proton pump inhibitors (PPIs), H2 blockers, antacids, and warfarin.

Common side effects of Symdeko include:

• headache,
• nausea,
• stuffy nose, and
• dizziness

Common side effects of Orkambi include:

• shortness of breath,
• sore throat and stuffy nose (nasopharyngitis),
• nausea,
• diarrhea,
• upper respiratory tract infection,
• fatigue,
• abnormal breathing,
• increased blood creatine phosphokinase,
• rash,
• gas,
• runny nose,
• flu symptoms,
• menstrual changes, and
• increases in blood pressure.

Symdeko (tezacaftor/ivacaftor tablets and ivacaftor tablets) is a combination drug indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508delmutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitrodata and/or clinical evidence.

Orkambi (lumacaftor/ivacaftor) is a combination of cystic fibrosis transmembrane conductance regulator (CFTR) potentiators indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene.

Symdeko may interact with other medicines such as:

Symdeko should be taken with fat-containing food. Symdeko may interact with:

• ketoconazole,
• fluconazole,
• grapefruit,
• Seville oranges,
• rifampin,
• rifabutin,
• phenobarbital,
• carbamazepine,
• phenytoin,
• St. John's wort,
• itraconazole,
• posaconazole,
• voriconazole,
• telithromycin,
• clarithromycin,
• erythromycin,
• digoxin,
• cyclosporine,
• everolimus,
• sirolimus, and
• tacrolimus

Tell your doctor all medications and supplements you use.

Orkambi may interact with:

• antifungals,
• antibiotics,
• rifampin,
• rifabutin,
• phenobarbital,
• carbamazepine,
• phenytoin,
• St. John's wort,
• benzodiazepines,
• immunosuppressants,
• digoxin,
• corticosteroids,
• ibuprofen, antidepressants,
• hormonal contraceptives,
• oral hypoglycemics,
• proton pump inhibitors (PPIs),
• H2 blockers,
• antacids, and
• warfarin

Tell your doctor all medications and supplements you use.

The adults and pediatric (ages 12 years and older) dose of Symdeko is one tablet (containing tezacaftor 100 mg/ivacaftor 150 mg) in the morning and one tablet (containing ivacaftor 150 mg) in the evening, approximately 12 hours apart.

The dose of Orkambi for adults and pediatric patients age 12 years and older is two tablets (each containing lumacaftor 200 mg/ivacaftor 125 mg) taken orally every 12 hours.